Titre : | Structural characterization of sulfoaildenafil, an analog of sildenafil (2009) |
Auteurs : | S. R. GRATZ ; M. ZELLER ; D. W. MINCEY ; C. L. FLURER |
Type de document : | Article : Périodique |
Dans : | Journal of Pharmaceutical and Biomedical Analysis (Vol.50, n°2, September 2009) |
Article en page(s) : | 228–231 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés MEDICAMENTS ; PSYCHOTROPES ; SILDENAFIL ; ANALYSE CHIMIQUE |
Résumé : | Phosphodiesterase type 5 (PDE-5) inhibitors represent a class of drugs used primarily in the treatment of erectile dysfunction. Currently, three PDE-5 inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for use in the United States: sildenafil citrate, tadalafil, and vardenafil hydrochloride trihydrate. A bulk material, labeled as an ingredient for a dietary supplement, was analyzed for the presence of PDE-5 inhibitors. The compound that was detected displayed structural similarities to sildenafil, and was characterized further using LC–MSn, FTICRMS, X-ray crystallography and NMR. The compound was given the name sulfoaildenafil. When compared to sildenafil, sulfoaildenafil contains a sulfur atom substitution for the oxygen atom in the pyrazolopyrimidine portion of the molecule, and a 3,5-dimethyl substitution on the piperazine ring, rather than the 4-methyl moiety. The X-ray crystallographic data indicate that the material in this sample is comprised of two polymorphs, which may affect the chemical and/or biological properties of any product formulated with this compound. |
Domaine : | Autres substances / Other substances |
Refs biblio. : | 26 |
Affiliation : | U.S. Food and Drug Administration, Forensic Chemistry Center, 6751 Steger Drive, Cincinnati, OH 45237, USA |
Accueil